Table 6.
A non-exhaustive summary of ongoing clinical trials evaluating other localised therapies in combination with immune checkpoint inhibition.
| Agent and NCT number | Combination | Study design | Status |
|---|---|---|---|
| Rose Bengal Disodium (PV-10) | |||
| NCT02557321 | PV-10 + Pembrolizumab | Phase 1, ICPI-refractory advanced melanoma | Recruiting |
| TLR agonists | |||
| NCT03865082 | Tilsotolimod (TLR-9 agonist) + Ipilimumab and Nivolumab | Phase 2, solid tumours | Recruiting |
| NCT04633278 | CMP-001 (TLR-9 agonist) + Pembrolizumab | Phase 2, HNSCC | Recruiting |
| NCT03435640 | NKTR-262 (TLR-7/8 agonist) + Nivolumab/pegylated-IL2 | Phase 1/2, advanced solid tumours | Active, not recruiting |
| NCT03301896 | LHC-165 (TLR-7 agonist) + PDR001 (anti-PD1) | Phase 1, advanced solid tumours | Active, not recruiting |
| NCT03317158 | BCG + Durvalumab + RT | Phase 1/2, NMIBC | Recruiting |
| STING agonists | |||
| NCT03010176 | MK-1454 + Pembrolizumab | Phase 1, advanced solid tumours | Active, not recruiting |
| NCT04220866 | MK-1454 + Pembrolizumab | Phase 2, HNSCC | Active, not recruiting |
| NCT03937141 | ADU-S100 + Pembrolizumab | Phase 2, HNSCC | Active, not recruiting |
| Oncolytic Peptides | |||
| NCT04796194 | LTX-315 + Pembrolizumab or Ipilimumab | Phase 2, advanced solid tumours | Recruiting |
| Thermal treatments | |||
| NCT03237572 | HIFU + Pembrolizumab | Phase 1, metastatic breast cancer | Recruiting |